Distinct gut microbiota signatures in older people with sarcopenic obesity and sarcopenia without obesityOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study investigated the gut microbiota of older adults with sarcopenic obesity (SO) and sarcopenia without obesity (Sar), compared with age-matched controls. Researchers used 16S rRNA gene sequencing targeting the V3-V4 regions to characterize microbial composition and diversity. The goal was to determine whether gut dysbiosis is associated with the development and progression of sarcopenia and sarcopenic obesity, a link previously suspected but not well documented.
Who was studied?
The sample was drawn from a community-based cohort of 1558 older adults (age 65 and older) in Shanghai, China, who underwent sarcopenia screening with the SARC-F questionnaire. Of these, 351 completed further assessment, and 60 participants were ultimately categorized using the Asian Working Group for Sarcopenia 2019 criteria and World Health Organization obesity criteria. The final groups were sarcopenic obesity (n=20), sarcopenia without obesity (n=18), and controls (n=22).
What were the most important findings?
Gut microbiota diversity and composition differed significantly between the sarcopenic obesity, sarcopenia, and control groups. Alpha diversity, measured by the Chao1 and ACE indices, was reduced specifically in the sarcopenic obesity group. Beta diversity, assessed by unweighted UniFrac PCoA, also differed significantly among the three groups, and LEfSe analysis identified 39 taxa with differential abundance across groups.
What are the greatest implications of this study?
The findings support the idea that gut microbiota alterations are distinctly linked to sarcopenic obesity rather than sarcopenia alone, with reduced diversity marking the combined obesity and muscle-loss phenotype. This suggests the gut microbiome could serve as a distinguishing biomarker between these related but distinct conditions in older adults. Identifying these taxa-level differences may help guide future microbiome-targeted approaches for prevention or management of sarcopenic obesity in aging populations.